Suspension of trading
Valuation Centessa Pharmaceuticals plc
Stocks
CNTA
US1523091007
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
21:00:00 23/06/2026 BST
|
5-day change | 1st Jan Change | ||
| 40.50 USD | +0.80% |
|
-.--% | +61.94% |
| 06-24 | Swiss Market Index Extends Rally; OC Oerlikon Shares Gain | MT |
| 06-24 | Eli Lilly Completes Acquisition of Centessa Pharmaceuticals | MT |
Company Valuation: Centessa Pharmaceuticals plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Market Cap 1 | 1,012 | 293.2 | 777.1 | 2,208 | 3,653 |
| Change | - | -71.03% | 165.01% | 184.18% | 65.43% |
| Enterprise Value (EV) 1 | 492.9 | -30.6 | 605.7 | 1,844 | 3,477 |
| Change | - | -106.21% | 2,079.61% | 204.46% | 88.56% |
| P/E | -2.22x | -1.34x | -5.07x | -8.13x | -17.2x |
| PBR | 2.06x | 0.87x | 3.33x | 5.53x | 7.08x |
| PEG | -0x | 0x | 0.2x | -0.3x | 0.6x |
| Capitalization / Revenue | - | - | 113,399,910x | - | 243,556,955x |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | -3.54x | 0.15x | -3.54x | -9.17x | -16.7x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -5.07 | -2.315 | -1.571 | -2.059 | -1.455 |
| Distribution rate | - | - | - | - | - |
| Net sales | - | - | 6.853 | - | 15 |
| EBITDA | -139.3 | -207.2 | -171 | -200.7 | -207.4 |
| EBIT 1 | -139.3 | -207.3 | -171.3 | -201.1 | -207.7 |
| Net income 1 | -381.9 | -216.2 | -151.1 | -235.8 | -197.5 |
| Net Debt 1 | -519.4 | -323.8 | -171.5 | -364.3 | -176.2 |
| Reference price 2 | 11.26 | 3.10 | 7.96 | 16.75 | 25.01 |
| Nbr of stocks (in thousands) | 89,901 | 94,596 | 97,629 | 131,845 | 146,076 |
| Announcement Date | 30/03/22 | 30/03/23 | 28/03/24 | 24/03/25 | 31/03/26 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 6.27B | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 8x | 26.2x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| 32.66x | 5.97x | 20.09x | -.--% | 23.67B | |
| Average | 26.77x | 26.46x | 15.68x | 0.32% | 38.94B | |
| Weighted average by Cap. | 26.72x | 25.33x | 15.90x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CNTA Stock
- Valuation Centessa Pharmaceuticals plc
Select your edition
All financial news and data tailored to specific country editions
